nach oben

Erschienen in:

27.02.2024 | Periphere arterielle Verschlusskrankheit | CME

Behandlung der chronischen peripheren arteriellen Verschlusskrankheit (pAVK)

Indikationsstellung, etagenspezifische Therapie und Follow-up-Regime

verfasst von: PD Dr. med. Christian-Alexander Behrendt, Franziska Heidemann, Alexander Meyer, Ursula Elisabeth Maria Werra, Ulrich Rother

Erschienen in: Gefässchirurgie | Ausgabe 2/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vielfältige klinische Manifestation der peripheren arteriellen Verschlusskrankheit (pAVK) macht eine konsequente Stufendiagnostik sowie eine stadiengerechte und an realistischen Zielen orientierte Behandlung erforderlich. Während präventivmedizinische Aspekte in allen Krankheitsstadien sowie vor, während und nach jeder invasiven Revaskularisation heute das Fundament der komplementären Behandlung ausmachen, können operative, interventionelle und Hybrideingriffe zur Symptomverbesserung und zum Beinerhalt durchgeführt werden. Die Auswahl der geeigneten Verfahren bzw. deren Kombination orientiert sich sowohl an patientenspezifischen Faktoren als auch an der lokalen Expertise und Infrastruktur. Alle technischen Erwägungen sollten dabei die komplementären Behandlungsalternativen berücksichtigen. Neben dem pAVK-assoziierten Fallvolumen der Klinik und den patientenspezifischen Risikofaktoren gilt insbesondere die Adhärenz zu leitliniengerechten Empfehlungen als wichtiger Prädiktor des langfristigen Behandlungsergebnisses.

Conte MS, Bradbury AW, Kolh P et al (2019) Global vascular guidelines on the management of chronic limb-threatening Ischemia. Eur J Vasc Endovasc Surg 58:S1–S109.e33PubMedCentralPubMed

Fitridge R, Chuter V, Mills J et al (2023) The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people With diabetes mellitus and a foot ulcer. Eur J Vasc Endovasc Surg

Nordanstig J, Behrendt CA, Baumgartner I et al (2023) European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication. Eur J Vasc Endovasc Surg

Arndt H, Nordanstig J, Bertges DJ et al (2022) A Delphi consensus on patient reported outcomes for registries and trials including patients with intermittent claudication: recommendations and reporting standard. Eur J Vasc Endovasc Surg 64:526–533PubMed

Song P, Rudan D, Zhu Y et al (2019) Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7:e1020–e1030PubMed

Baubeta Fridh E, Andersson M, Thuresson M et al (2017) Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study. Eur J Vasc Endovasc Surg 54:480–486PubMed

Kreutzburg T, Peters F, Kuchenbecker J et al (2021) Editor’s choice—the Germanvasc score: a pragmatic risk score predicts five year amputation free survival in patients with peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 61:248–256PubMed

Sigvant B, Lundin F, Wahlberg E (2016) The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 51:395–403PubMed

Alushi K, Hinterseher I, Peters F et al (2022) Distribution of mobile health applications amongst patients with symptomatic peripheral arterial disease in Germany: a cross-sectional survey study. J Clin Med 11:498PubMedCentralPubMed

10.

Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S et al (2020) Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis. Vasc Med 25:106–117PubMed

11.

Li Y, Rother U, Rosenberg Y et al (2023) A prospective survey study on the education and awareness about walking exercise amongst inpatients with symptomatic peripheral arterial disease in Germany. Vasa

12.

Pastori D, Farcomeni A, Milanese A et al (2020) Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 120:866–875PubMed

13.

Peters F, Kreutzburg T, Riess HC et al (2020) Editor’s choice—optimal pharmacological treatment of symptomatic peripheral arterial occlusive disease and evidence of female patient disadvantage: an analysis of health insurance claims data. Eur J Vasc Endovasc Surg 60:421–429PubMed

14.

Rosenberg Y, Görtz H, Rother U et al (2022) Empfehlungen zur konservativen Therapie und Sekundärprävention der peripheren arteriellen Verschlusskrankheit (PAVK): Eine evidenzbasierte Informationsbroschüre für Betroffene. Gefässchirurgie 27:39–45

15.

Rother U, Dörr G, Malyar N et al (2023) How German vascular surgeons and angiologists judge walking exercise for patients with PAD. Vasa 52:224–229PubMed

16.

Wolbert L, Kreutzburg T, Zyriax BC et al (2022) A cross-sectional survey study on the nutrition patterns of patients with peripheral artery disease. Vasa

17.

Chuter V, Schaper N, Hinchliffe R et al (2023) Performance of non-invasive bedside vascular testing in the prediction of wound healing or amputation among people with foot ulcers in diabetes: a systematic review. Diabetes Metabolism Res e3701:

18.

Chuter V, Schaper N, Mills J et al (2023) Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: a systematic review. Diabetes Metabolism Res e3683:

19.

Chuter V, Schaper N, Mills J et al (2023) Effectiveness of revascularisation for the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metabolism Res e3700:

20.

Behrendt CA, Mills JL (2023) Witnessing the evolution of peripheral arterial disease interventions: survival of the fit, diversity, adaptation to environmental niches, and missing links. Eur J Vasc Endovasc Surg

21.

Bradbury AW, Moakes CA, Popplewell M et al (2023) A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial. Lancet 401:1798–1809PubMed

22.

Farber A, Menard MT, Conte MS et al (2022) Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med 387:2305–2316PubMed

23.

Lyons OT, Behrendt C‑A, Björck M (2023) Beyond wires and knives: what can we learn from BEST-CLI and BASIL-2? Eur J Vasc Endovasc Surg 66:1–3PubMed

24.

Popplewell MA, Meecham L, Davies HOB et al (2023) Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) prospective cohort study and the generalisability of the BASIL‑2 randomised controlled trial. Eur J Vasc Endovasc Surg

25.

Kotov A, Peters F, Debus ES et al (2021) The prospective Germanvasc cohort study. Vasa 50:446–452PubMed

26.

Peters F, Behrendt CA (2023) Limb related outcomes of endovascular vs. Open surgical revascularisation in patients with peripheral arterial occlusive disease: a report from the prospective Germanvasc cohort study. Eur J Vasc Endovasc Surg 66:85–93PubMed

27.

Fontaine R, Kim M, Kieny R (1954) Surgical treatment of peripheral circulation disorders. Helv Chir Acta 21:499–533PubMed

28.

Rutherford RB, Baker JD, Ernst C et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26:517–538PubMed

29.

Søgaard M, Nielsen PB, Eldrup N et al (2023) Epidemiological trends and projections of incidence, prevalence, and disease related mortality associated with peripheral arterial disease: observations using nationwide Danish data. Eur J Vasc Endovasc Surg 66:662–669PubMed

30.

International Diabetes F (2015) IDF Diabetes Atlas, 7. Aufl. Belgium

31.

Stoberock K, Kaschwich M, Nicolay SS et al (2021) The interrelationship between diabetes mellitus and peripheral arterial disease. Vasa 50:323–330PubMed

32.

Kreutzburg T, Peters F, Riess HC et al (2020) Editor’s choice—comorbidity patterns among patients with peripheral arterial occlusive disease in Germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg 59:59–66PubMed

33.

Kaschwich M, Peters F, Hischke S et al (2020) Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease—a health insurance claims data analysis. Vasa 49:493–499PubMed

34.

Criqui MH, Fronek A, Barrett-Connor E et al (1985) The prevalence of peripheral arterial disease in a defined population. Circulation 71:510–515PubMed

35.

Behrendt CA, Thomalla G, Rimmele DL et al (2023) Editor’s choice—prevalence of peripheral arterial disease, abdominal aortic aneurysm, and risk factors in the Hamburg city health study: a cross sectional analysis. Eur J Vasc Endovasc Surg 65:590–598PubMed

36.

Kröger K, Stang A, Kondratieva J et al (2006) Prevalence of peripheral arterial disease—results of the Heinz Nixdorf recall study. Eur J Epidemiol 21:279–285PubMed

37.

Diehm C, Schuster A, Allenberg JR et al (2004) High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172:95–105PubMed

38.

Hirsch AT, Criqui MH, Treat-Jacobson D et al (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. Jama : J Am Med Assoc 286:1317–1324

39.

Behrendt C‑A, Uhl C, Görtz H et al (2023) Die Wahrnehmung der peripheren arteriellen Verschlusskrankheit (PAVK) als Volkskrankheit: Behandeln wir nur die Spitze eines riesigen Problems? Gefässchirurgie 28:58–60

40.

Søgaard M, Nordanstig J, Eldrup N et al (2023) A thought-provoking statement regarding the treatment of patients with peripheral arterial disease. Vasa 52:77–80PubMed

41.

Visseren FLJ, Mach F, Smulders YM et al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiolog

42.

Fowkes FG, Rudan D, Rudan I et al (2013) Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382:1329–1340PubMed

43.

Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMed

44.

Kröger K, Scheliga S, Derissen M et al (2023) Raucherentwöhnung bei Patienten mit peripherer arterieller Verschlusskrankheit. Gefässchirurgie

45.

Prompers L, Schaper N, Apelqvist J et al (2008) Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 51:747–755PubMedCentralPubMed

46.

American Diabetes Association (2021) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care 44:S111–S124

47.

Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255–323PubMed

48.

Rodionov RN, Peters F, Marschall U et al (2021) Initiation of SGLT2 Inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a health claims data analysis. Eur J Vasc Endovasc Surg

49.

Martinez-Aguilar E, Orbe J, Fernández-Montero A et al (2017) Reduced high-density lipoprotein cholesterol: a valuable, independent prognostic marker in peripheral arterial disease. J Vasc Surg 66:1527–1533.e1521PubMed

50.

Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C‑reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481–2485PubMed

51.

Peters F, Kuchenbecker J, Kreutzburg T et al (2020) Long-term effectiveness and safety of initiating statin therapy after index revascularization in patients with peripheral arterial occlusive disease. J Am Heart Assoc 9:e18338PubMedCentralPubMed

52.

Unger T, Borghi C, Charchar F et al (2020) 2020 international society of hypertension global hypertension practice guidelines. Hypertension 75:1334–1357PubMed

53.

Criqui MH, Aboyans V (2015) Epidemiology of peripheral artery disease. Circ Res 116:1509–1526PubMed

54.

Kotov A, Blasche DA, Peters F et al (2022) The impact of chronic kidney disease on mid-term outcomes after revascularisation of peripheral arterial occlusive disease: results from a prospective cohort study. J Clin Med 11:

55.

Mcdermott MM, Mehta S, Greenland P (1999) Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 159:387–392PubMed

56.

Sigvant B, Lundin F, Nilsson B et al (2011) Differences in presentation of symptoms between women and men with intermittent claudication. BMC Cardiovasc Disord 11:39PubMedCentralPubMed

57.

Rose GA (1962) The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27:645–658PubMedCentralPubMed

58.

Larsen ASF, Reiersen AT, Jacobsen MB et al (2017) Validation of the vascular quality of life questionnaire‑6 for clinical use in patients with lower limb peripheral arterial disease. Health Qual Life Outcomes 15:184PubMedCentralPubMed

59.

Mcdermott MM, Ferrucci L, Liu K et al (2010) Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc 58:1256–1262PubMedCentralPubMed

60.

Behrendt CA, Bischoff MS, Schwaneberg T et al (2019) Population based analysis of gender disparities in 23,715 percutaneous endovascular revascularisations in the metropolitan area of Hamburg. Eur J Vasc Endovasc Surg 57:658–665PubMed

61.

Behrendt CA, Sigvant B, Kuchenbecker J et al (2020) Editor’s choice—international variations and sex disparities in the treatment of peripheral arterial occlusive disease: a report from VASCUNET and the international consortium of vascular registries. Eur J Vasc Endovasc Surg 60:873–880PubMedCentralPubMed

62.

Woods BOB (1991) Clinical evaluation of the peripheral vasculature. Cardiol Clin 9:413–427PubMed

63.

Khan NA, Rahim SA, Anand SS et al (2006) Does the clinical examination predict lower extremity peripheral arterial disease? JAMA 295:536–546PubMed

64.

Aboyans V, Criqui MH, Abraham P et al (2012) Measurement and interpretation of the ankle-brachial index: a scientific statement from the American heart association. Circulation 126:2890–2909PubMed

65.

Alagha M, Aherne TM, Hassanin A et al (2021) Diagnostic performance of ankle-brachial pressure index in lower extremity arterial disease. Surg J 7:e132–e137

66.

Shabani Varaki E, Gargiulo GD, Penkala S et al (2018) Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods. BioMed Eng OnLine 17:61PubMedCentralPubMed

67.

Birkett ST, Harwood AE, Caldow E et al (2021) A systematic review of exercise testing in patients with intermittent claudication: a focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions. PLoS ONE 16:e249277PubMedCentralPubMed

68.

Mcdermott MM, Ades PA, Dyer A et al (2008) Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg 48:1231–1237 (1237 e1231)PubMedCentralPubMed

69.

Mcdermott MM, Guralnik JM, Tian L et al (2020) Comparing 6‑minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease. J Vasc Surg 71:988–1001PubMed

70.

Amouzegar A, Mehran L, Hasheminia M et al (2016) The predictive value of metabolic syndrome for cardiovascular and all-cause mortality: Tehran lipid and glucose study. Diabetes Metabolism Res

71.

Normahani P, Mustafa C, Shalhoub J et al (2021) A systematic review and meta-analysis of the diagnostic accuracy of point-of-care tests used to establish the presence of peripheral arterial disease in people with diabetes. J Vasc Surg 73:1811–1820PubMed

72.

Wukich DK, Shen W, Raspovic KM et al (2015) Noninvasive arterial testing in patients with diabetes. Foot Ankle Int 36:1391–1399PubMed

73.

Hoyer C, Sandermann J, Petersen LJ (2013) The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg 58:231–238PubMed

74.

Günther JS, Knieling F, Träger AP et al (2023) Targeting muscular hemoglobin content for classification of peripheral arterial disease by noninvasive multispectral optoacoustic tomography. JACC Cardiovasc Imaging 16:719–721PubMed

75.

Träger AP, Günther JS, Raming R et al (2024) Hybrid ultrasound and single wavelength optoacoustic imaging reveals muscle degeneration in peripheral artery disease. Photoacoustics 35:100579PubMed

76.

Eiken FL, Pedersen BL, Baekgaard N et al (2019) Diagnostic methods for measurement of peripheral blood flow during exercise in patients with type 2 diabetes and peripheral artery disease: a systematic review. Int Angiol 38:62–69PubMed

77.

Rother U, Krenz K, Lang W et al (2017) Immediate changes of angiosome perfusion during tibial angioplasty. J Vasc Surg 65:422–430PubMed

78.

Rother U, Lang W, Horch RE et al (2018) Pilot assessment of the angiosome concept by intra-operative fluorescence angiography after tibial bypass surgery. Eur J Vasc Endovasc Surg 55:215–221PubMed

79.

Rother U, Lang W, Horch RE et al (2017) Microcirculation evaluated by intraoperative fluorescence angiography after tibial bypass surgery. Ann Vasc Surg 40:190–197PubMed

80.

Collins R, Cranny G, Burch J et al (2007) A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease. Health Technol Assess 11:iii–iv (xi–xiii, 1–184)PubMed

81.

Takahashi M, Koga Y, Bussaka H et al (1984) The value of digital subtraction angiography in peripheral vascular diseases. Br J Radiol 57:123–132PubMed

82.

Conte MS, Bradbury AW, Kolh P et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 69:3S–125S e140PubMedCentralPubMed

83.

Adegbola A, Behrendt CA, Zyriax BC et al (2022) The impact of nutrition on the development and progression of peripheral artery disease: a systematic review. Clin Nutr 41:49–70PubMed

84.

Dovzhanskiy D, Behrendt C‑A, Görtz H et al (2023) Das große Verbesserungspotenzial in der multimodalen Basisbehandlung der peripheren arteriellen Verschlusskrankheit (pAVK): ein Aufruf zum flächendeckenden Ausbau der pAVK-Gehtrainingsgruppen in Deutschland. Gefässchirurgie 28:235–239

85.

Rümenapf G, Rother U, Behrendt C et al (2021) Gehtraining bei Claudicatio intermittens: kritische Analyse. Gefässchirurgie 26:92–96

86.

Barua RS, Rigotti NA, Benowitz NL et al (2018) 2018 ACC Expert consensus decision pathway on tobacco cessation treatment: a report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 72:3332–3365PubMed

87.

Ding N, Sang Y, Chen J et al (2019) Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol 74:498–507PubMedCentralPubMed

88.

Krabbe B, Espinola-Klein C, Malyar N et al (2023) Health effects of e‑cigarettes and their use for smoking cessation from a vascular perspective. Vasa 52:81–85PubMed

89.

Twine CP, Kakkos SK, Aboyans V et al (2023) Editor’s choice—European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases. Eur J Vasc Endovasc Surg 65:627–689PubMed

90.

Behrendt CA, Kreutzburg T, Nordanstig J et al (2022) The OAC(3)-PAD risk score predicts major bleeding events one year after hospitalisation for peripheral artery disease. Eur J Vasc Endovasc Surg 63:503–510PubMed

91.

Peters F, Behrendt CA (2022) External validation of the OAC3-PAD risk score to predict major bleeding events using the prospective Germanvasc cohort study. Eur J Vasc Endovasc Surg

92.

Williams B, Mancia G, Spiering W et al (2019) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol 77:71–159PubMed

93.

Frank U, Nikol S, Belch J et al (2019) ESVM guideline on peripheral arterial disease. Vasa 48:1–79PubMed

94.

Choudhry AJ, Shaw PM (2023) Endovascular aorto-Iliac reconstruction vs. Aortobifemoral bypass as first choice for a durable revascularization for aorto-Iliac occlusive disease. Vasc Endovascular Surg 57:88–92PubMed

95.

Indes JE, Pfaff MJ, Farrokhyar F et al (2013) Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther 20:443–455PubMed

96.

Ballotta E, Gruppo M, Mazzalai F et al (2010) Infrapopliteal arterial reconstructions for limb salvage in patients aged 〉 or = 80 years according to preoperative ambulatory function and residential status. Surgery 148:119–128PubMed

97.

Boufi M, Ejargue M, Gaye M et al (2021) Systematic review and meta-analysis of endovascular versus open repair for common femoral artery atherosclerosis treatment. J Vasc Surg 73:1445–1455PubMed

98.

Starodubtsev V, Mitrofanov V, Ignatenko P et al (2022) Editor’s choice—Hybrid vs. Open surgical reconstruction for iliofemoral occlusive disease: a prospective randomised trial. Eur J Vasc Endovasc Surg 63:557–565PubMed

99.

Koeckerling D, Raguindin PF, Kastrati L et al (2023) Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis. Eur Heart J 44:935–950PubMedCentralPubMed

100.

Feldman DN, Armstrong EJ, Aronow HD et al (2018) SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv 92:124–140PubMed

101.

Kim Y, Thangappan K, Decarlo CS et al (2022) Outcomes of femoropopliteal bypass for lifestyle-limiting claudication in the endovascular era. J Surg Res 279:323–329PubMed

102.

Zeller T, Beschorner U, Pilger E et al (2015) Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P‑II randomized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv 8:1614–1622PubMed

103.

Levin SR, Farber A, Osborne NH et al (2021) Tibial bypass in patients with intermittent claudication is associated with poor outcomes. J Vasc Surg 73:564–571 e561PubMed

104.

Kobayashi T, Hamamoto M, Okazaki T et al (2021) Long-term results of distal bypass for intermittent claudication. Vasc Endovascular Surg 55:5–10PubMed

105.

Darling JD, Mccallum JC, Soden PA et al (2016) Predictive ability of the society for vascular surgery wound, ischemia, and foot Infection (WIfI) classification system following infrapopliteal endovascular interventions for critical limb ischemia. J Vasc Surg 64:616–622PubMedCentralPubMed

106.

Robinson WP, Loretz L, Hanesian C et al (2017) Society for Vascular Surgery Wound, Ischemia, foot Infection (WIfI) score correlates with the intensity of multimodal limb treatment and patient-centered outcomes in patients with threatened limbs managed in a limb preservation center. J Vasc Surg 66:488–498.e482PubMed

107.

Aboyans V, Ricco JB, Bartelink MEL et al (2018) Editor’s choice—2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS). Eur J Vasc Endovasc Surg 55(3):305–368. https://doi.org/10.1016/j.ejvs.2017.07.018CrossRefPubMed

108.

Gerhard-Herman MD, Gornik HL, Barrett C et al (2017) 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary. Vasc Med 22:NP1–NP43PubMed

109.

Venermo M, Sprynger M, Desormais I et al (2019) Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European society of cardiology working group on aorta and peripheral vascular diseases and the European society for vascular surgery. Eur J Prev Cardiolog 26:1971–1984

Titel: Behandlung der chronischen peripheren arteriellen Verschlusskrankheit (pAVK)
Indikationsstellung, etagenspezifische Therapie und Follow-up-Regime
verfasst von: PD Dr. med. Christian-Alexander Behrendt
Franziska Heidemann
Alexander Meyer
Ursula Elisabeth Maria Werra
Ulrich Rother
Publikationsdatum: 27.02.2024
Verlag: Springer Medizin
Schlagwörter: Periphere arterielle Verschlusskrankheit
Periphere arterielle Verschlusskrankheit
Arteriosklerose
Gefäßchirurgie
Viszerale Ischämie
Thrombozytenaggregationshemmer
Statine
ACE-Hemmer
Ernährung
Sport
Rauchen und Raucherentwöhnung
Erschienen in: Gefässchirurgie / Ausgabe 2/2024
Print ISSN: 0948-7034
Elektronische ISSN: 1434-3932
DOI: https://doi.org/10.1007/s00772-024-01086-9

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Infektdiagnostik des diabetischen Fußsyndroms

Die Behandlung von Menschen mit einem diabetischen Fußsyndrom ist und bleibt eine interdisziplinäre Herausforderung

Konzepte äußerer Entlastung – Offloading im Alltag der Fußsprechstunde

Revaskularisation beim diabetischen Fußsyndrom? Wann und wie?

Mitteilungen der SGG

Das diabetische Fußsyndrom – ein ungeliebtes Kind der Gefäßmedizin?